Evidence map›Paper›PMID 41402130›Full record

ArticleFuture oncology (London, England)2026

Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer.

Yanan Duan, Shuping Cheng, Wenru Qin, Bing Zou, Bingjie Fan, Linlin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanan DuanDepartment of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Shuping ChengDepartment of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Wenru QinDepartment of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Bing ZouDepartment of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Bingjie FanDepartment of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Linlin WangDepartment of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study assessed the efficacy and safety of radiotherapy (RT) plus immunochemotherapy in oligometastatic esophageal cancer (OMEC).

methodsA single-center retrospective study of OMEC patients who received immunochemotherapy from Jan 2019 to Jan 2022.

resultsAbout 226 patients were included, which consisted of 108 cases in the RT plus immunochemotherapy group (iCRT), and 118 cases in the immunochemotherapy group (iCT). With a median follow-up of 22.2 months, the median progression-free survival (PFS) was 13.0 months for the iCRT group and 7.7 months for the iCT group (

conclusionCompared to immunochemotherapy alone, RT plus immunochemotherapy showed survival benefits with manageable safety for OMEC patients.

Indexed as

ChemoradiotherapyEsophageal NeoplasmsImmunotherapyAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm MetastasisProgression-Free SurvivalRetrospective StudiesTreatment OutcomechemotherapyEsophageal squamous cell carcinomaimmunotherapyoligometastasesradiotherapy

Identifiers

PMID41402130
PMCPMC12915874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.